Lenvatinib Mesylate CAS 857890-39-2 Assay 98.0 ~ 102.0% Warshada

Lenvatinib Mesylate (CAS: 857890-39-2) waa horjooge afka iyo bartilmaameedka badan leh ee VEGFR1-3, FGFR1-4, PDGFR, KIT, iyo RET, oo leh hawlo ka hortag ah oo awood leh.Lenvatinib Mesylate waa daaweeyaha tyrosine kinase (RTK) inhibitor kaas oo leh xulashada VEGFR2.Waxay soo bandhigaysaa firfircoonida antineoplastic, waxaana lagu tilmaamay daaweynta bukaanada leh deegaanka soo noqnoqda ama metastatic, horusocod, radioactive iodine (RAI) -oo kala sooca kansarka tayroodhka.Lenvatinib Mesylate waxaa markii ugu horreysay ansixiyay Maamulka Cuntada iyo Dawooyinka ee Mareykanka (FDA) Febraayo 13, 2015, ka dib waxaa ansixiyay Wakaaladda Dawooyinka iyo Qalabka Caafimaadka ee Japan (PMDA) Mar 26, 2015, waxaana oggolaaday Wakaaladda Daawooyinka Yurub (EMA) May 28, 2015. Waxaa loo sameeyay oo loo suuq geeyey sida Lenvima® by Eisai.Lenvatinib Mesylate waa tayroosin kinase inhibitor ah oo afka laga qaato oo leh qaab xidhid gaar ah kaas oo si xushmad leh u joojinaya dhaqdhaqaaqyada kinase ee xuubka korriinka endothelial vascular (VEGF), marka lagu daro kuwa kale ee proangiogenic iyo oncogenic ee la xidhiidha tyrosine kinases loo maleynayo inay ku lug leeyihiin kordhinta burada .Waxa loo tilmaamay daawaynta horusocodka radioiodine-refractory kala soocidda kansarka tayroodhka.LenvimaWaxaa loo istcimaalay in lagu daweeyo kansarka tayroodh kala duwan (DTC), oo ah nooc ka mid ah kansarka tayroodhka oo aan hadda lagu daweyn karin iodine shucaac ah oo sii socda.LENVIMA waxaa lala isticmaalaa dawo kale oo loo yaqaan everolimus si loogu daweeyo dadka qaangaarka ah ee qaba nooca kansarka kelyaha ee loo yaqaan kansarka unugyada sare ee kelyaha (RCC) ka dib hal koorso oo lagu daaweeyay daawo kale oo kansarka ka hortagga ah.